The clinical relevance of avexitide’s GLP-1R antagonism is underscored by its therapeutic use in treating postbariatric hypoglycemia (PBH), a condition characterized by excessive insulin secretion following gastric bypass surgery. This evidence concerns the gene INS and Hypoglycemia.